Abstract |
Canine and rodent tumors covalently bind the fluorinated 2-nitroimidazole, CCI-103F, in a way that immunohistochemical analysis shows is consistent with the location of tumor hypoxia. We have now developed a rapid, quantitative, and non-radioactive enzyme linked immunosorbent assay for the binding of CCI-103F in biopsy samples of spontaneous canine tumors. Issues of antigen stability during tissue processing, calibration of the ELISA, and the use of biopsy samples for measuring tumor hypoxia by the ELISA approach are addressed.
|
Authors | J A Raleigh, E M Zeman, M Rathman, J K LaDine, J M Cline, D E Thrall |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 22
Issue 3
Pg. 403-5
( 1992)
ISSN: 0360-3016 [Print] United States |
PMID | 1310494
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Animals
- Cell Hypoxia
(physiology)
- Dogs
- Enzyme-Linked Immunosorbent Assay
- Liposarcoma
(physiopathology, veterinary)
- Neoplasms
(physiopathology, veterinary)
- Nitroimidazoles
(metabolism)
- Sarcoma, Synovial
(physiopathology, veterinary)
|